Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCT2031240352
jRCT2031240352Active, not recruitingNot Applicable

Phase 3 a long-term administration study of NTa53 in Patients with Allergic Conjunctivitis

Nitto Medic Co., Ltd.0 sites120 target enrollmentStarted: October 7, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
120
Primary Endpoint
Safety
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomized Controlled Trial
Intervention Model
Single Assignment
Primary Purpose
Treatment Purpose
Masking
Open(masking Not Used)

Eligibility Criteria

Ages
7age old over to No limit (—)
Sex
All

Inclusion Criteria

  • •Provided signed, written informed consent.
  • •Has a positive result from a Type I allergy test.

Exclusion Criteria

  • •Eye disease other than allergic conjunctivitis is present and requires treatment.
  • •Other protocol-specified exclusion criteria may apply.

Outcomes

Primary Outcomes

Safety

Adverse Events, Ophthalmologic Examination and Clinical Examination

Efficacy

Subjective Ocular Symptom Score, Objective Ocular Findings Score, Quality Of Life Survey

Secondary Outcomes

No secondary outcomes reported

Investigators

Similar Trials

Unknown
Phase 3
A phase III study of TAK-536 (long-term use study)Essential hypertension
JPRN-jRCT2080220837Takeda Pharmaceutical Company Limited360
Completed
Phase 3
ong Term Follow-up Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and Bulbar Muscular Atrophy (SBMA)
JPRN-UMIN000001010Department of Neurology, Nagoya University School of Medicine152
Recruiting
Not Applicable
A phase 3 long-term treatment study to evaluate the safety and efficacy of AKP-022 in patients with uterine fibroids (LUNA2)
jRCT2031240570ASKA Pharmaceutical Co., Ltd.350
Active, not recruiting
Not Applicable
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - AVX-303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage I
EUCTR2008-001486-28-FRAvexa Limited1,866
Active, not recruiting
Not Applicable
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - 303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage I
EUCTR2008-001486-28-BEAvexa Limited1,866